| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/27/2001 | US6194469 Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids |
| 02/27/2001 | US6194467 Diabetes remedies |
| 02/27/2001 | US6194466 Such as risperidone, lithobid, and olanzapine, by administering a pharmaceutically acceptable salt of n,n-dimethylimidocarbonimidic diamide (such as metformin hydrochloride) |
| 02/27/2001 | US6194465 Administering acetamido-, nitro-, or amino-mono- or disubstituted n-alkyl benzamide compounds such as n-tert-butyl-4-acetamidobenzamide for prophlaxis or treatment of an inflammatory bowel condition in a patient |
| 02/27/2001 | US6194462 Pharmaceutical preparation containing nimesulide for oral administration |
| 02/27/2001 | US6194461 Nitrone derivatives |
| 02/27/2001 | US6194460 Composition for treating cough induced by angiotensin converting enzyme inhibitors |
| 02/27/2001 | US6194459 Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants |
| 02/27/2001 | US6194458 1-(2-methoxyphenyl)-1-oxo-2-aza-(s)-4-i-butyl-4-phenylbutane, for example; treating various conditions including transplantation rejection of organs or tissues in a patient; immunosuppressant compositions |
| 02/27/2001 | US6194456 Method for inhibiting inflammation |
| 02/27/2001 | US6194455 Prevention herpes outbreak; administering sucralfate, lidocaine and antibiotic |
| 02/27/2001 | US6194454 Cyano containing oxamic acids and derivatives as thyroid receptor ligands |
| 02/27/2001 | US6194453 Antiinflammatory agents; therapy for immunology conditions |
| 02/27/2001 | US6194451 Prevent release tumor necrosis factor; antiinflammatory agents |
| 02/27/2001 | US6194450 Polyaromatic heterocyclic compounds and pharmaceutical compositions comprised thereof |
| 02/27/2001 | US6194449 Allosteric adenosine receptor modulators |
| 02/27/2001 | US6194448 N, N-disubstituted amides that inhibit the binding of integrins to their receptors |
| 02/27/2001 | US6194445 Use of pramipexole in the treatment of restless legs syndrome |
| 02/27/2001 | US6194442 Antiinflammatory agent |
| 02/27/2001 | US6194441 Gramnegative and grampositive bacteria |
| 02/27/2001 | US6194440 Small molecule carbamate or urea hair growth compositions and uses |
| 02/27/2001 | US6194439 Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| 02/27/2001 | US6194438 Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one, and compositions and methods for inhibiting abnormal cell growth comprising said derivatives |
| 02/27/2001 | US6194437 Non-peptide bombesin receptor antagonists |
| 02/27/2001 | US6194436 NK-1 receptor antagonists for the treatment of cancer |
| 02/27/2001 | US6194434 Cycloalkylaminomethylpyrrolidine derivatives |
| 02/27/2001 | US6194433 Sexual dysfunction in females |
| 02/27/2001 | US6194432 Prevention and treatment of migraine, cluster and other recurrent headaches using leukotriene antagonist drugs |
| 02/27/2001 | US6194431 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| 02/27/2001 | US6194430 Viral treatment |
| 02/27/2001 | US6194428 Use of 5-substituted pyridine and hexahydroquinoline-3 carboxylic acid derivatives for treating diseases of the central nervous system |
| 02/27/2001 | US6194427 Brain disorders; psychological disorders; sleep disorders; anticonvulsants |
| 02/27/2001 | US6194426 5,6,7,8 tetrahydroindolizines derivatives |
| 02/27/2001 | US6194425 Viricides, antitumor agents |
| 02/27/2001 | US6194424 Arylacetamides and their use as medicaments |
| 02/27/2001 | US6194423 Fused isoquinolines as dopamine receptor ligands |
| 02/27/2001 | US6194422 Antibiotic; amyloidoses therapy |
| 02/27/2001 | US6194421 Parasiticides |
| 02/27/2001 | US6194420 Blood disorders; reduce platelet concentration |
| 02/27/2001 | US6194419 Therapy for sexual disorders; a 5-oxoimidazolo(1,2-a)pyrimidine-6-carboxylic ester |
| 02/27/2001 | US6194416 Central nervous system disorders; alzheimer's disease |
| 02/27/2001 | US6194415 Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| 02/27/2001 | US6194414 Radioprotectors |
| 02/27/2001 | US6194413 Hemoregulatory compounds |
| 02/27/2001 | US6194412 Mixtures derived from grains of Eugenia Jambolana Lamarck preparation and use of said mixtures and some of their constituents as medicaments |
| 02/27/2001 | US6194411 3(2H)-pyridazinone derivatives and pharmaceutical compositions containing these compounds |
| 02/27/2001 | US6194410 Antiserotonine agents; nervous system and psychological disorders |
| 02/27/2001 | US6194409 Heterocyclic derivatives and their use as antithrombotic agents |
| 02/27/2001 | US6194408 Parasiticides |
| 02/27/2001 | US6194407 Incontinence |
| 02/27/2001 | US6194405 3,3a,8,12b-tetrahydro-n-methyl-2h-dibenzo(3,4:6,7)-cyclohepta( 1,2-b)-furan-2-methanamine, for example; anxiolytic agents, antidepressants, sleep and sexual disorders, psychological, cardiovascular and gastrointestinal disorders |
| 02/27/2001 | US6194404 Process for the isolation of galanthamine |
| 02/27/2001 | US6194402 Administering a compound to stimulate the effects of somatotropins to patients after acute deconditioning such as that which may result from immobilization, surgery, or major injury, e.g., hip fracture; |
| 02/27/2001 | US6194401 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of α-glycerophosphoric acid |
| 02/27/2001 | US6194400 Use of amino acid precursors for the treatment of addictions |
| 02/27/2001 | US6194399 Aryldiamine derivatives useful as antibacterial agents |
| 02/27/2001 | US6194397 Enzyme inhibitors of acetylcholinesterase and butyrylcholinesterase; increased hepatoprotective and antienzyme activities; n'-substituted phosphonoalkyl-, phosphono- or thiophosphonocytisines |
| 02/27/2001 | US6194395 Liquid injectable and oral solid pharmaceutical dosage forms of a mixture or complex of cladribine and a water solubilizer, a cyclodextrin; storage stability |
| 02/27/2001 | US6194392 Administering to a patient suffering from swelling associated with brain tumours involving tissue of the group consisting of underperfused tissue and pathological tissue an antiswelling agent and a hyaluronic acid to aid penetration |
| 02/27/2001 | US6194391 Cs-87 (title compound) induces a transient mutation in hiv-1 at the 70th codon of the reverse transcriptase region of the virus; administering to a human in need of therapy with a drug that induces a mutation in hiv-1 at another location |
| 02/27/2001 | US6194390 Administering hydroxyurea and a 2'-fluoropurine-dideoxy-nucleoside selected from the group of 2'-fluoro-2',3'-dide-oxyadenosine,-dideoxyinosine, and -dideoxyguanosine with a carrier or excipient; viricides; retroviruses; plant viruses |
| 02/27/2001 | US6194388 Immunomodulatory oligonucleotides |
| 02/27/2001 | US6194387 6-O-aklyl erythromycin B oxime |
| 02/27/2001 | US6194386 Labelled peptide compounds |
| 02/27/2001 | US6194382 Selectively antagonize excitatory opioid receptor functions, but not inhibitory opioid receptor functions, in myenteric neurons in the intestinal tract and of the central nervous system; enhances the potency of opiod peptides |
| 02/27/2001 | US6194380 Agents for promoting bone formation |
| 02/27/2001 | US6194206 Use of oligonucleotide telomerase inhibitors to reduce telomere length |
| 02/27/2001 | US6194205 Multistep process using conditionally immortalized antigen-presenting cells which are engineered to express antigen of interest, adding leukocytic cells, and culturing mixture to activate the t cells |
| 02/27/2001 | US6194181 Producing epothiolones in a culture medium by providing microorganisms such as myxobacteria which produce epothiolones, and adding a complex-forming agent soluble in the culture medium, such as cyclodextrins; antitumor agents |
| 02/27/2001 | US6194171 Also vectors, transformed cells; useful for expression in cells for the purposes of identifying agonists or antagonists of ataxin-2-binding protein function |
| 02/27/2001 | US6194153 Methods for determining risk of developing alzheimer's disease by detecting mutations in the presenilin 1 (PS-1) gene |
| 02/27/2001 | US6194139 Using a psoralen compound |
| 02/27/2001 | US6194020 Conserving procyanidins(catechins); candy |
| 02/27/2001 | US6194004 Dry mix formulation for bisphosphonic acids |
| 02/27/2001 | US6194003 Process for making flurbiprofen lozenges |
| 02/27/2001 | US6194002 Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid |
| 02/27/2001 | US6194000 Analgesic immediate and controlled release pharmaceutical composition |
| 02/27/2001 | US6193996 Device for the transdermal delivery of diclofenac |
| 02/27/2001 | US6193993 Suppository containing an antidementia medicament |
| 02/27/2001 | US6193992 Administering apomorphine to increase intraclitoral blood flow and vaginal wall blood flow on stimulation but less than amount that induces nausea to treat sexual dysfunction |
| 02/27/2001 | US6193991 Nontoxic; controlled release of drugs |
| 02/27/2001 | US6193989 Administering drug comprising ivermectin, benzyl alcohol, polyvinylpyrrolidone, n-methyl-2-pyrrolidone, and glycerin by injecting animal to treat parasite infection |
| 02/27/2001 | US6193969 Preventing, ameliorating, or treating septic shock or its symptoms by administering igg (immunoglobulin g) fab fragments reactive towards tnf.alpha.(tumor nercosis factor), wherein igg fab fragments are derived from polyclonal igg |
| 02/27/2001 | US6193966 Administering bispecific protein or peptide molecule, comprising a first binding determinate which binds to fc.alpha.receptor without being blocked by immunoglobulin a and second binding determinant which binds to target antigen |
| 02/27/2001 | US6193965 Administering therapeutically effective amount of reagent which modulates kinase activity for treating cell proliferative disorder associated with c-jun n-terminal kinase disorder, |
| 02/27/2001 | US6193962 Pharmaceutical formulation comprising a 2-aminoacetamide derivative and an ion exchange resin |
| 02/27/2001 | US6193961 Personal care composition containing a homogeneous terpolymer of an n-vinyl lactam and a polysiloxane |
| 02/27/2001 | US6193957 For prophylaxis and therapy of airway hyperresponsiveness or inflammatory reactions, e.g., asthma, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, inflammatory bowel disease or rheumatoid arthritis |
| 02/27/2001 | US6193954 Formulations for pulmonary delivery of dopamine agonists |
| 02/27/2001 | US6193949 Method of sire selection using naloxone challenge tests and kits thereof |
| 02/27/2001 | US6193595 Methods and apparatus for performing processing operations on a slaughtered animal or part thereof |
| 02/27/2001 | US6192887 Comprising compound selected from sodium dodecyl sulfate, lithium dodecyl sulfate, lauric acid or a pharmaceutically acceptable salt thereof in a sufficient amount to attain a virucidal effect against a non-enveloped virus |
| 02/27/2001 | CA2317064A1 Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| 02/27/2001 | CA2317053A1 New pyridine derivatives, the process for preparing them and the pharmaceutical compositions that contain them |
| 02/27/2001 | CA2316662A1 Use of crf antagonists and related compositions |
| 02/27/2001 | CA2316647A1 Treatment or prevention of coccidiosis |
| 02/27/2001 | CA2232789C Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product |
| 02/27/2001 | CA2213775C Cancer metastasis inhibitor containing a streptococcus agalactiae ia type or ib type surface polysaccharide as a main ingredient |
| 02/27/2001 | CA2191230C 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease |
| 02/27/2001 | CA2190952C Use of a naphthalenesulfonic acid compound for inhibiting retroviral infection |